Phases précoces tumeurs solides
ARROW (BLU-667-1101)
A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Paris
NICOLAS GIRARD